Proactive Investors - Run By Investors For Investors

Medlab Clinical receives preliminary results from NanoStat™ trial

NanoStat™ refers to the delivery of the drug Atorvastatin using NanoCelle™.
lab
NanoCelle™ delivers medicine in a tiny particle form in a spray into the mouth

Medlab Clinical Ltd (ASX:MDC) has received and analysed the results of the NanoStat™ trial from Zenith in New Zealand. 

NanoStat is an investigative new sub-micron spray delivering a dosage of Atorvastatin in four pumps applied to the oro-buccal membrane (skin inside the mouth).

Atorvastatin is a statin medication used to lower cholesterol and was selected as it had specific comparative benefits when being tested in Medlab’s drug delivery platform (mouth spray).

Atorvastatin is predominantly provided to patients in tablet form.

Medlab aims to deliver medicinal cannabis using this drug delivery platform.

READ: Medlab outlines business development objectives at open day

Medlab’s CEO Dr Sean Hall said: “For those who recall why we undertook NanoCelle™ work with Atorvastatin, Atorvastatin had inherent properties that would test the NanoCelle™ capabilities beyond most generic drugs and our cannabis programs.

“These results further show the potential and widespread capabilities of the NanoCelle™ delivery platform.”

Post-results work shows benefits of spray over tablet ingestion

In work undertaken at our main laboratory in Alexandria post results, Medlab has improved NanoStat™ with data now indicating a 2 + times better blood level of free atorvastatin compared to the oral ingested Atorvastatin tablet.

Further, the work demonstrated that peak blood concentrations of free Atorvastatin was achieved in about 30 minutes, as previously compared to 53 minutes on the oral tablet.

Medlab considers the data extremely interesting as it has highlighted several areas of improvement which had previously not been obvious.

Moving forward Medlab intends to perfect this technique, develop the product further and look for potential new patents for Atorvastatin in light of the program findings to date.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

cannabis facility
January 24 2019
The company is breaking into the large and lucrative market in the golden state
1540909388_Marijuana-stethoscope.jpg
October 31 2018
The firm wants to become the first publicly listed, globally focused, pure cannabis company
cannabis facility
January 24 2019
The company will capitalize on the need for indoor-grown, pharmaceutical-grade cannabis

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use